(Q54384410)

29 May 2018

title

Prevalence of CYP2C19 polymorphisms in the Lebanese population. (English)

1 reference

29 May 2018

main subject

Lebanon

0 references

author name string

Isabelle Djaffar Jureidini

1

1 reference

29 May 2018

Nabil Chamseddine

2

1 reference

29 May 2018

Sose Keleshian

3

1 reference

29 May 2018

Rania Naoufal

4

1 reference

29 May 2018

Laila Zahed

5

1 reference

29 May 2018

Noha Hakime

6

1 reference

29 May 2018

publication date

5 March 2011

1 reference

29 May 2018

Molecular Biology Reports

published in

1 reference

29 May 2018

volume

38

1 reference

29 May 2018

issue

8

1 reference

29 May 2018

page(s)

5449-5452

1 reference

29 May 2018

https://scigraph.springernature.com/pub.10.1007/s11033-011-0700-y

exact match

0 references

cites work

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Aspirin and clopidogrel resistance: an emerging clinical entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Communicating medical news--pitfalls of health care journalism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-011-0700-Y

CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip.

21 January 2018

1 reference

12 December 2020

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

1 reference

12 December 2020

Impact of P-glycoprotein on clopidogrel absorption

1 reference

12 December 2020

Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure

1 reference

12 December 2020

Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness

1 reference

12 December 2020

10.1007/S11033-011-0700-Y

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018